Allyx Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-03-03.
Allyx Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on March 3, 2026. The filing reports $3.32M sold. Its industry group is Biotechnology. It names Stephen Bloch (Executive Officer, Director), Stephen Strittmatter (Director), Paul Fonteyne (Director) (SEC Form D, March 3, 2026).
Sell to companies like Allyx Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Allyx Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Allyx Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Connecticut, filed within 90 days of this one, largest first.
Get an email when Allyx Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Allyx Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Allyx Therapeutics, Inc. →Get the full cited report on Allyx Therapeutics, Inc.
What the filing shows about Allyx Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Allyx Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Allyx Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Allyx Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $3.32M, on the same scale — one filing against the whole group's total, so it sits low by construction.
No amount other than ordinary course employment compensation is being paid to officers and directors.
Stephen Bloch is named as Executive Officer and Director on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Stephen Strittmatter is named as Director on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Paul Fonteyne is named as Director on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Gregory Ho is named as Director on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Robert Bettigole is named as Director on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Timothy Siegert is named as Executive Officer on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
Jennifer Gabler is named as Executive Officer on the Form D that Allyx Therapeutics, Inc. filed with the SEC on 3 March 2026, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2026-03-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Allyx Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Allyx Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allyx Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Allyx Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Allyx Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Allyx Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/allyx-therapeutics-inc-form-d-26000002